Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies

Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression

(2023) Manuel Salavisa et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)

(2023) Kyle Smoot et al.   Multiple Sclerosis Journal

Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis

(2023) E.M.E. Coerver et al.   Multiple Sclerosis and Related Disorders

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

(2023) John R Corboy et al.   LANCET NEUROLOGY

How patients with multiple sclerosis acquire disability

(2022) Fred D. Lublin et al.   BRAIN

Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study

(2022) Emilio Portaccio et al.   BRAIN

Shift of multiple sclerosis onset towards older age

(2022) Luca Prosperini et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis

(2022) Maëlle Chappuis et al.   JOURNAL OF NEUROLOGY

Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM

(2022) Zanga Gisela et al.   NEUROLOGICAL RESEARCH

Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study

(2022) Daniele Michelis et al.   Multiple Sclerosis and Related Disorders

Considering patient age when treating multiple sclerosis across the adult lifespan

(2021) Dejan Jakimovski et al.   Expert Review of Neurotherapeutics

Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis

(2021) Hans-Peter Hartung et al.   CURRENT OPINION IN NEUROLOGY

Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study

(2021) Aurora Zanghì et al.   Neurotherapeutics

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis

(2021) Eva M. M. Strijbis et al.   JAMA Neurology

What happens after fingolimod discontinuation? A multicentre real-life experience

(2021) Doriana Landi et al.   JOURNAL OF NEUROLOGY

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis

(2021) Luca Prosperini et al.   Neurology-Neuroimmunology & Neuroinflammation

Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age

(2021) Dejan Jakimovski et al.   Multiple Sclerosis and Related Disorders

Long-term drug treatment in multiple sclerosis: safety success and concerns

(2020) Dejan Jakimovski et al.   Expert Opinion On Drug Safety

Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity

(2020) Anne-Laure Kaminsky et al.   JOURNAL OF NEUROLOGY

Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab

(2020) Chiara Rosa Mancinelli et al.   Multiple Sclerosis Journal

Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis

(2020) Tobias Monschein et al.   JOURNAL OF NEUROLOGY

SUSTAINED DISEASE REMISSION AFTER DISCONTINUATION OF DISEASE MODIFYING TREATMENTS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

(2020) Matteo Pasca et al.   Multiple Sclerosis and Related Disorders

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score

(2020) Gabriel Bsteh et al.   EUROPEAN JOURNAL OF NEUROLOGY

Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes

(2019) Hajime Yano et al.   Multiple Sclerosis and Related Disorders

Multiple sclerosis

(2018) Alan J Thompson et al.   LANCET

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report

(2017) Regina Berkovich   Multiple Sclerosis and Related Disorders

Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab

(2017) Jan Fagius et al.   Multiple Sclerosis and Related Disorders

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

(2017) Ann Marie Weideman et al.   Frontiers in Neurology

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

(2016) J. Bonenfant et al.   EUROPEAN JOURNAL OF NEUROLOGY

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

(2016) Ilya Kister et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Treatment withdrawal in relapsing−remitting multiple sclerosis: a retrospective cohort study

(2015) G. Lus et al.   EUROPEAN JOURNAL OF NEUROLOGY

Medication withdrawal may be an option for a select group of patients in relapsing-remitting multiple sclerosis

(2013) Guilherme Sciascia do Olival et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity

(2011) Małgorzata Siger et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

(2010) V. Devonshire et al.   EUROPEAN JOURNAL OF NEUROLOGY

A basic introduction to fixed-effect and random-effects models for meta-analysis

(2010) Michael Borenstein et al.   Research Synthesis Methods